These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28957559)

  • 1. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.
    Plumpton CO; Alfirevic A; Pirmohamed M; Hughes DA
    Rheumatology (Oxford); 2017 Oct; 56(10):1729-1739. PubMed ID: 28957559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
    Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
    J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
    Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
    J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
    [No Abstract]   [Full Text] [Related]  

  • 4. A lifetime economic research of universal HLA-B*58:01 genotyping or febuxostat initiation therapy in Chinese gout patients with mild to moderate chronic kidney disease.
    Hong Y; Chen X; Li Z; Zhang X; Zhou C; Wang Y; Wang G; Wu W; Zhou D; Feng Li H
    Pharmacogenet Genomics; 2023 Feb; 33(2):24-34. PubMed ID: 36729770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.
    Park DJ; Kang JH; Lee JW; Lee KE; Wen L; Kim TJ; Park YW; Park SH; Lee SS
    Arthritis Care Res (Hoboken); 2015 Feb; 67(2):280-7. PubMed ID: 25047754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?
    Teng GG; Tan-Koi WC; Dong D; Sung C
    Pharmacogenomics; 2020 Mar; 21(4):279-291. PubMed ID: 32180492
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
    Dong D; Tan-Koi WC; Teng GG; Finkelstein E; Sung C
    Pharmacogenomics; 2015 Nov; 16(16):1781-93. PubMed ID: 26554739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
    Jutkowitz E; Dubreuil M; Lu N; Kuntz KM; Choi HK
    Semin Arthritis Rheum; 2017 Apr; 46(5):594-600. PubMed ID: 27916277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
    Chong HY; Lim YH; Prawjaeng J; Tassaneeyakul W; Mohamed Z; Chaiyakunapruk N
    Pharmacogenet Genomics; 2018 Feb; 28(2):56-67. PubMed ID: 29176400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M; Pandor A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.
    Saokaew S; Tassaneeyakul W; Maenthaisong R; Chaiyakunapruk N
    PLoS One; 2014; 9(4):e94294. PubMed ID: 24732692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
    Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A
    Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of febuxostat in chronic gout.
    Beard SM; von Scheele BG; Nuki G; Pearson IV
    Eur J Health Econ; 2014 Jun; 15(5):453-63. PubMed ID: 23719971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of febuxostat in patients with gout in Spain.
    Perez-Ruiz F; Díaz-Torné C; Carcedo D
    J Med Econ; 2016 Jun; 19(6):604-10. PubMed ID: 26855041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy.
    Plumpton CO; Yip VL; Alfirevic A; Marson AG; Pirmohamed M; Hughes DA
    Epilepsia; 2015 Apr; 56(4):556-63. PubMed ID: 26046144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
    Hill-McManus D; Marshall S; Soto E; Lane S; Hughes D
    Value Health; 2018 Dec; 21(12):1373-1381. PubMed ID: 30502780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of allopurinol and febuxostat for the management of gout.
    Jutkowitz E; Choi HK; Pizzi LT; Kuntz KM
    Ann Intern Med; 2014 Nov; 161(9):617-26. PubMed ID: 25364883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Ponzo MG; Miliszewski M; Kirchhof MG; Keown PA; Dutz JP
    J Cutan Med Surg; 2019; 23(6):595-601. PubMed ID: 31378082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data.
    Lin LW; Teng GG; Lim AYN; Yoong JS; Zethraeus N; Wee HL
    Int J Rheum Dis; 2019 Apr; 22(4):545-554. PubMed ID: 30556300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.